Date: April 16, 2021

Source: Office of Scientific R&D, College of Pharmacy 

JNU has obtained an implied license for clinical trials for an AXL/FLT3/NTRK inhibitor named HH30134, one  of the first category of drugs according to China’s drug registration regulation. The drug was jointly developed by JNU, Shanghai Haihe Biopharma Co., Ltd. (SHB), and the Chinese Academy of Sciences's Shanghai Institute of Materia Medica (SIMM). According to the Center for Drug Evaluation of the National Medical Products Administration (CDE), HH30134 was approved on April 14 for use in clinical trials in China to treat advanced malignant solid tumors.

Code-named JND30134 at the early stage of research and development, HH30134 was developed by Prof. Ding Ke’s team at JNU, Academician Ding Jian and Prof. Geng Meiyu’s team of SIMM, and SHB. In August 2019, SHB paid over 800 million RMB in  contract value for the global development rights to JND32066.

The implied license listed on CDE website

According to SHB’s official website, the Phase I international multi-center clinical study of HH30134 was carried out in Australia, with its very first patient on April 8. The clinical trial was designed to evaluate HH30134's safety, tolerance and pharmacokinetic characteristics in patients with advanced solid tumors. The study is  to be conducted synchronously in Australia and China.

The achievement being introduced in the report

At the press conference of the 2020 Annual Report on the Transformation of China's Scientific and Technological Achievements (in Universities and Research Institutes) in Beijing on April 14, this achievement was introduced as a transformation case. Pooling data from 3,450 public universities and research institutes in China in 2019 as samples, the report comprehensively analyzes the progress, effectiveness and main problems of the transformation of scientific and technological achievements in these institutions. It also reveals that in 2019 JNU ranked in the top three in terms of the contract amount of transforming scientific and technological achievements through transfer, license and investment. The report also includes the innovation experience of JNU’s scientific and technological achievement transformation mechanism as a typical case.